Earnings Outlook For Xeris Biopharma Holdings
Portfolio Pulse from Benzinga Insights
Xeris Biopharma Holdings (NASDAQ:XERS) is scheduled to release its quarterly earnings report on March 6, 2024, with an estimated EPS of $-0.10. Analysts and investors are looking for an earnings beat and positive guidance for the next quarter. Despite beating EPS estimates in the past, such outcomes have sometimes led to a drop in share price the following day. Over the last year, XERS shares have increased by 123.33%, indicating a bullish outlook from long-term shareholders.
March 05, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Xeris Biopharma Holdings is expected to report an EPS of $-0.10 for the upcoming quarter. Historical data shows mixed stock price reactions to earnings beats. Shares have significantly appreciated over the past year.
While XERS is expected to report an EPS of $-0.10, past performance indicates that even beating the EPS estimate does not guarantee a positive short-term stock price movement. However, the significant yearly increase in share price suggests a strong long-term bullish sentiment among investors.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100